AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Israeli fintech Morning acquired for $150 million by Italy's TeamSystem
2
Have missiles from the Iranian-backed Houthis discovered a loophole in Israeli air defenses?
3
Can a tweet derail a $900 million cyber-tech deal?
4
SQream CEO Ami Gal steps down after 14 years
5
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
More news

Teva

20 stories about Teva
מפעל תרופות טבע

Credit Line and Bonds: Teva's Financial Catch

12.08.19|Uri Tal-Tene
At first glance, Teva’s second quarter reports provided little cause for drama. The small print reveals a very different story
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beat Analysts’ Consensus, But Its Big Battles Are Still Up Ahead

08.08.19|Sophie Shulman
Teva ends the second quarter of 2019 down a CFO, with negative cash flow and the threat of lawsuits that could cost billions. In his call with analysts, CEO Kare Schultz hinted at the possibility of future layoffs, but Teva still handed out $240 million worth of annual bonuses to senior executives
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beats Analysts on Second Quarter Operating Income, Revenues

07.08.19|CTech
The company also announced chief financial officer Michael McClellan will be stepping down after two years for personal reasons related to family
קאר שולץ מנכל טבע

Rivals' Earning Reports Should Have Teva's Shareholders Worried

05.08.19|Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
אתר טבע כפר סבא

Teva to Pay California $69 Million in Narcolepsy Drug Settlement

30.07.19|Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
אתר טבע כפר סבא

Former Execs, Directors, to Pay Teva $50 Million for Part in Bribery Damages

25.07.19|Tomer Ganon
A recently reached settlement will see the Israeli drugmaker receive compensation for the fines it paid U.S. and Israeli authorities after being charged with conspiracy to violate the anti-bribery provisions of the Foreign Corrupt Practices Act in 2016
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Where is Kåre Schultz?

17.07.19|Sophie Shulman
The Danish CEO was drafted to save Teva straight off the successful turnaround of pharma company Lundbeck. Since then, the Israeli company’s market cap dropped by 66%, but Schultz has stayed mum
אתר טבע כפר סבא

Teva Falls on Pre-Market Trading After Morgan Stanley Downgrade

15.07.19|CTech
Teva recently reached an $85 million settlement with the State of Oklahoma regarding its alleged role in the state’s opioid crisis, but is still facing many more claims
אתר טבע כפר סבא

Court Approves One Teva Opioid Settlement, Many More to Come

25.06.19|Hezi Sternlicht
The settlement will see Teva will pay Oklahoma a one-time payment of $85 million to settle claims that it had played a role in exacerbating the U.S. opioid use epidemic there
אתר טבע כפר סבא

Fitch Downgrades Teva, Keeps Outlook at Negative

10.06.19|Hezi Sternlicht
Fitch pins the downgrade on the drugmaker's slow revenue growth, persisting cost challenges and downward pressure on generic drug prices, and the company's legal trouble in the U.S.
מטה חברת טבע תרופות

Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition

28.05.19|Hezi Sternlicht
Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud
מטה חברת טבע תרופות

Teva Reaches $85 Million Settlement in Oklahoma Opioid Damages Suit

27.05.19|Hezi Sternlicht
Teva is one of several opioid manufacturers being sued in the U.S. by different states and private entities for its alleged role in the nation's opioid addiction crisis
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
מטה חברת טבע תרופות

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices

15.05.19|Hezi Sternlicht, Ran Abramson, and Tomer Ganon
A 524-page civil lawsuit filed Friday in the U.S. alleges that 20 generic drugmakers colluded to influence drug prices, with executives meeting regularly to set prices and split the market
הבורסה לניירות ערך רחוב אחוזת בית תל אביב

Teva no Longer Largest Company on TASE After U.S. Legal Troubles Sink Stock

13.05.19|Lilach Baumer
International Flavors & Fragrances (IFF), which listed on the Tel Aviv exchange in October following its acquisition of Israel-based Frutarom, has now surpassed the Israeli drugmaker
מטה חברת טבע תרופות

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19|Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
כנס קנאביס פרי דוידסון סאייקי מדיקל

For Medical Cannabis Users, the Biggest Problem Is a Consistent Dose, Says Syqe Medical CEO

07.05.19|Orna Yefet
Perry Davidson, founder and CEO of cannabis inhaler company Syqe Medical, spoke Monday at Calcalist's cannabis conference in Tel Aviv
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva’s Copaxone Successors Are Still Far From Success

05.05.19|Hezi Sternlicht
Teva’s first quarter report for 2019, published Thursday, shows that while the drugmaker is progressing with its financial rehabilitation program, its net debt to EBITDA ratio is leaving the company in dangerous waters
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
אתר טבע כפר סבא

Teva Discontinues Development of Cluster Headache Drug

24.04.19|Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
Previous ArticlesMore Articles